Avid Bioservices Inc (CDMO)

[jakedogman1]

from nilogen IASLC2015

www.nilogen.com/file/7/download?token=cmOHvF7J

§The ex-vivo system is reliable to demonstrate drug combination
effects on the tumor immune microenvironment of fresh patient
samples.
§Bavituximab, alone and in combination with docetaxel, induces
activation of tumor infiltrating lymphocytes as demonstrated by a
significant increase in IFN-?, TNF-a, and GM-CSF with
corresponding decrease in IL-10 secretion.
§Bavituximab’s response appears to correlate with low PD-L1
expression in the tumor samples.
§M1 polarization of tumor associated macrophages is likely
involved in bavituximab-mediated activation of tumor infiltrating
lymphocytes.
§Combination of bavituximab with PD-1/PD-L1 inhibitors may
enhance the immunomodulatory efficacy in lung cancer.

So does the Asco sunrise tie it all together...

http://abstracts.asco.org/199/AbstView_199_190902.html

Conclusions: Baseline PD-L1 expression in a subset of SUNRISE patients demonstrated that PD-L1 expression (TC0) was associated with a significantly prolonged OS compared to positive PD-L1 expression (TC1/2/3) in patients receiving D+B.

Granted the d+p did as well but the p value was worthless and lots of noise... So what does bavi plus a keytruda or opdivo do with low pdl-1 patients? And the MOS one might get would not be compared with the MOS of folks that respond... it will be compared with the folks that have low pdl ...

Just the thought of this working would be worth a lot more than zero IP value.